天美传媒

Skip to content
University News

天美传媒 researchers awarded up to $22M to study a hidden driver of aging

BETTER LIVING THROUGH SCIENCE: 鈥淥ur hope is that by dialing down retrotransposons, we can help people remain healthier, stronger, and mentally sharper as they age,鈥� says project lead Vera Gorbunova, the Doris Johns Cherry Professor in the Department of Biology at 天美传媒. (天美传媒 photo / J. Adam Fenster)

The ARPA-H鈥揻unded collaboration will test whether reducing DNA-triggered inflammation can help older adults stay healthier for longer.

What if people could stay healthier, stronger, and mentally sharper as they grow older鈥攏ot by treating diseases one by one but by slowing a biological process that drives aging itself? A new 鈥搇ed research effort will test whether a drug originally developed to treat HIV can quiet a chronic immune response triggered by the body鈥檚 own DNA, to help preserve overall health and function later in life.

The project is supported by a contract of up to $22 million over five years from the (ARPA-H), a federal agency created to support high-impact biomedical projects that could lead to transformative advances in health. Its highly competitive awards are designed to accelerate bold ideas that, if successful, could reshape how medicine approaches major health challenges. The 天美传媒 team is one of several selected by the agency鈥檚 PROactive Solutions for Prolonging Resilience (PROSPR) program.

The 天美传媒 effort is led by , the Doris Johns Cherry Professor in the and currently codirector of the and the Upstate NY Comparative Biology of Aging Nathan Shock Center, and 聽brings together 天美传媒 researchers from the River Campus, from the and codirector of the University鈥檚 Resilience Research Center, and from the , along with collaborators from Brown University, University of Connecticut, The University of Texas Medical Branch, University of Texas Health Houston, University of Nebraska, and Transposon Therapeutics.

鈥淎ging underlies many chronic diseases, but it鈥檚 rarely targeted directly,鈥� Gorbunova says. 鈥淭his project builds on the 天美传媒鈥檚 long-standing leadership in aging research and gives us a unique opportunity to partner with other leading institutions to address one of the root causes of age-related decline.鈥�

While scientists know that aging underlies many chronic diseases, the mechanisms driving this decline are poorly understood. One of the drivers may be hidden in our DNA: As people grow older, their cells can begin to mistake parts of their own genetic material for viral threats, triggering chronic inflammation that contributes to physical and cognitive decline.

The project鈥攐ne of the first and most comprehensive efforts to test an intervention aimed directly at the biological mechanisms of aging鈥攚ill test whether this internal 鈥渇alse alarm鈥� can be safely reduced, helping older adults stay healthier for longer.

鈥淭he work being led by Professor Gorbunova is an excellent example of the ways in which large-scale public and private partnerships can address some of the most pressing challenges of human health and well-being,鈥� says University President Sarah Mangelsdorf. 鈥淲e鈥檙e grateful to Congress and our delegation, in particular, for their continued support of ARPA-H and the high-impact, transformative research it funds. We deeply appreciate ARPA-H and its recognition of Professor Gorbunova鈥檚 research and of the 天美传媒鈥檚 leadership in biomedical science and its application to human health.鈥�

A hidden driver of aging

The research focuses on retrotransposons, virus-like sequences called selfish genetic elements that make up a large portion of the human genome. Unlike actual viruses, transposons cannot exit the cell and infect other cells, but they seek to propagate themselves within the host DNA. Transposons are normally kept dormant, but research over the past decade by Gorbunova and her colleagues has shown that retrotransposons become increasingly active with age, leading to inflammation that contributes to tissue decline.

鈥淲hen we are young, our cells are good at keeping retrotransposons suppressed,鈥� Gorbunova says. 鈥淎s we age, that control weakens, and the immune system begins to respond as if the body is under viral attack.鈥�

This kind of persistent, age-related immune response has been linked to a wide range of age-related diseases, such as neurodegeneration, cancer, diabetes, and autoimmune diseases. Gorbunova鈥檚 lab was among the first to show that LINE-1 retrotransposons can directly activate interferon signaling鈥攖he same antiviral defense system cells use to detect viral infections鈥攃reating a 鈥渇alse alarm鈥� in the form of age-related inflammation.

鈥淲e have known for years that non-infection related inflammation increases with age and is linked to poor aging outcomes,鈥� says Andrew Brack, ARPA-H program manager and creator of the PROSPR program. 鈥淏ecause LINE-1 retrotransposons have recently been reported to increase inflammation as we age, we are excited about the possibility that anti-retroviral therapies, which have the added benefit of a long history of safety in non-diseased populations, will extend healthspan.鈥�

From discovery to intervention

Building on those discoveries, the ARPA-H鈥揻unded project will test whether a drug originally developed to treat HIV can suppress retrotransposon activity and reduce biological aging. The drug, TPN-101, inhibits reverse transcriptase鈥攁n enzyme that retrotransposons rely on to replicate.

In earlier preclinical studies, similar drugs reduced interferon signaling and chronic inflammation associated with aging. The new project will extend that work by testing long-term treatment in animal models, followed by a randomized clinical trial in humans. Heffner will lead the clinical trial.

鈥淭ranslating the Gorbunova Lab鈥檚 pioneering discoveries into human clinical trials is an extraordinary opportunity to turn fundamental aging science into therapies that could meaningfully improve health in later life,鈥� says Heffner, who collaborates with Gorbunova and Seluanov on the executive committee of the University鈥檚 Aging Institute, led by Medina-Walpole.

The clinical phase of the study will enroll 200 healthy adults ages 60 to 65, who will receive either TPN-101 or a placebo for 48 weeks. The researchers will assess changes in intrinsic capacity, a World Health Organization framework that includes mobility, cognition, vitality, sensory function, and psychological health, along with molecular markers of biological aging, physical performance, and overall health.

The study could help pave the way for therapies designed to preserve overall health and function as people grow older.

鈥淥ur hope is that by dialing down retrotransposons, we can help people remain healthier, stronger, and mentally sharper as they age,鈥� Gorbunova said. 鈥淭hat would be a profound shift in how we think about aging and intervention.鈥�

Elected officials applaud landmark award

Elected officials praised the award as a major investment in biomedical innovation and a recognition of 天美传媒鈥檚 leadership in aging research.

US Senator Charles Schumer: 鈥溙烀来解�檚 scientific advancement is recognized around the globe and is an integral part of maintaining America鈥檚 leadership in discovering new medical breakthroughs to advance human health. This $22 million ARPA-H award is an exciting opportunity for 天美传媒, and I will continue to fight to bring new federal investment to advance this groundbreaking work.鈥�

US Senator Kirsten Gillibrand: 鈥淎s ranking member of the Senate Special Committee on Aging, I鈥檓 pleased to see vital health and science investments addressing some of our most pressing challenges to healthy aging and longevity. This collaboration has the potential to address linkages between aging and chronic illnesses, as well as inform treatments to allow people to live longer, healthier lives. Congratulations to Dr. Gorbunova and the 天美传媒 for this tremendous award, I look forward to the outcomes of this effort and continued leadership in aging research.鈥�

Congressman Joe Morelle: 鈥淭he 天美传媒 is one of the world鈥檚 leading universities in scientific discovery, so it is no surprise to me that they鈥檝e once again been chosen to spearhead a new, cutting-edge research initiative. Congratulations to Dr. Gorbunova and the entire 天美传媒 team on this achievement, and as Vice Ranking Member of the House Appropriations Committee, I鈥檓 going to continue working to secure more opportunities like this for our researchers, students, and innovators in our community.鈥�

Congresswoman Claudia Tenney: 鈥淭he 天美传媒 plays a critical role in supporting hospitals and healthcare providers that serve patients across NY-24, and ARPA-H awarding this grant will have tangible, local impact. This investment strengthens our regional health care system, supports high-skilled medical and research jobs, and helps ensure that patients in our communities benefit from cutting-edge advances developed here in Upstate New York.鈥�

Congressman Nick Langworthy: 鈥淭his landmark ARPA-H award is a powerful vote of confidence in the 天美传媒鈥檚 leadership in biomedical research and its ability to turn cutting-edge scientific ideas into real-world health breakthroughs. I was proud to support ARPA-H funding as part of the FY26 minibus the House passed that is making projects like this possible. Research that targets the underlying drivers of aging has the potential to transform how we approach chronic disease, improve quality of life for our seniors, and keep the United States at the forefront of medical innovation, all while reinforcing the University鈥檚 role as a national hub for life-saving science and workforce talent.鈥�